Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Mar;71(3):583–586. doi: 10.1038/bjc.1995.113

Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.

A Bamias 1, D Cunningham 1, V Nicolson 1, A Norman 1, M Hill 1, M Nicolson 1, M O'Brien 1, A Webb 1, A Hill 1
PMCID: PMC2033623  PMID: 7880742

Abstract

Previous trials of adjuvant chemotherapy for oesophagogastric cancer have shown only modest or no improvement in survival. However, the regimens used in these studies produce low response rates in patients with advanced disease. ECF is a new regimen which results in higher response rates and may therefore be more effective in the adjuvant setting. Twenty-nine patients who had undergone a potentially curative resection for oesphagogastric carcinoma were treated with ECF [epirubicin 50 mg m-2 and cisplatin 60 mg m-2 for 18 weeks]. The median age was 52.5 years. Three patients had oesophageal tumours, 14 had tumours of the oesophagogastric junction (OGJ) and 12 had gastric tumours. All were adenocarcinomas apart from one undifferentiated carcinoma. One patient had stage I disease, nine stage II, 17 stage II and two stage IV. The mean number of chemotherapy cycles per patient was 5.2 (range 2-8). The median follow-up was 8.4 months (1.5-36.3 months). Eleven patients relapsed during follow-up (38%). One patient had an anastomotic recurrence and ten patients distant metastases. Overall 3 year survival was 61.5% (95% confidence interval 42-79); 3 year survival in stage II was 50% (21.2-86.3) and in stage III 65.6% (40-86). Chemotherapy was well tolerated, with grade 3/4 toxicity as follows: leucopenia 13.5%, nausea and vomiting 10%, diarrhoea 3.5%, infection 3.5% and thrombocytopenia 3.5%. There were no treatment-related deaths. We conclude that ECF can be administered safely as adjuvant treatment to patients with surgically resected gastro-oesophageal carcinoma. The results, especially in patients with stage III disease, are encouraging and support the investigation of this regimen within a prospective randomised trial.

Full text

PDF
583

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allum W. H., Hallissey M. T., Ward L. C., Hockey M. S. A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group. Br J Cancer. 1989 Nov;60(5):739–744. doi: 10.1038/bjc.1989.350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cocconi G. Chemotherapy of advanced gastric carcinoma: to be completely rewritten? Ann Oncol. 1994 Jan;5(1):8–11. doi: 10.1093/oxfordjournals.annonc.a058701. [DOI] [PubMed] [Google Scholar]
  3. Coggon D., Inskip H. Is there an epidemic of cancer? BMJ. 1994 Mar 12;308(6930):705–708. doi: 10.1136/bmj.308.6930.705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ellis P., Cunningham D. Management of carcinomas of the upper gastrointestinal tract. BMJ. 1994 Mar 26;308(6932):834–838. doi: 10.1136/bmj.308.6932.834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Findlay M., Cunningham D., Norman A., Mansi J., Nicolson M., Hickish T., Nicolson V., Nash A., Sacks N., Ford H. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994 Sep;5(7):609–616. doi: 10.1093/oxfordjournals.annonc.a058932. [DOI] [PubMed] [Google Scholar]
  6. Girling D. J., Clark P. I. Randomized trials in the treatment of cancer of the esophagus. J Clin Oncol. 1992 Jul;10(7):1031–1033. doi: 10.1200/JCO.1992.10.7.1031. [DOI] [PubMed] [Google Scholar]
  7. Hermans J., Bonenkamp J. J., Boon M. C., Bunt A. M., Ohyama S., Sasako M., Van de Velde C. J. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993 Aug;11(8):1441–1447. doi: 10.1200/JCO.1993.11.8.1441. [DOI] [PubMed] [Google Scholar]
  8. Herskovic A., Martz K., al-Sarraf M., Leichman L., Brindle J., Vaitkevicius V., Cooper J., Byhardt R., Davis L., Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992 Jun 11;326(24):1593–1598. doi: 10.1056/NEJM199206113262403. [DOI] [PubMed] [Google Scholar]
  9. Kelsen D., Atiq O. T., Saltz L., Niedzwiecki D., Ginn D., Chapman D., Heelan R., Lightdale C., Vinciguerra V., Brennan M. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol. 1992 Apr;10(4):541–548. doi: 10.1200/JCO.1992.10.4.541. [DOI] [PubMed] [Google Scholar]
  10. Lerner A., Gonin R., Steele G. D., Jr, Mayer R. J. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol. 1992 Apr;10(4):536–540. doi: 10.1200/JCO.1992.10.4.536. [DOI] [PubMed] [Google Scholar]
  11. Lokich J. J., Ahlgren J. D., Gullo J. J., Philips J. A., Fryer J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989 Apr;7(4):425–432. doi: 10.1200/JCO.1989.7.4.425. [DOI] [PubMed] [Google Scholar]
  12. MacDonald J. S., Schein P. S., Woolley P. V., Smythe T., Ueno W., Hoth D., Smith F., Boiron M., Gisselbrecht C., Brunet R. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med. 1980 Oct;93(4):533–536. doi: 10.7326/0003-4819-93-4-533. [DOI] [PubMed] [Google Scholar]
  13. McCulloch P. Should general surgeons treat gastric carcinoma? An audit of practice and results, 1980-1985. Br J Surg. 1994 Mar;81(3):417–420. doi: 10.1002/bjs.1800810332. [DOI] [PubMed] [Google Scholar]
  14. Rahamim J., Cham C. W. Oesophagogastrectomy for carcinoma of the oesophagus and cardia. Br J Surg. 1993 Oct;80(10):1305–1309. doi: 10.1002/bjs.1800801029. [DOI] [PubMed] [Google Scholar]
  15. Stacey R. G., Filshie J., Skewes D. Percutaneous insertion of Hickman-type catheters. Br J Hosp Med. 1991 Dec;46(6):396–398. [PubMed] [Google Scholar]
  16. Thompson G. B., van Heerden J. A., Sarr M. G. Adenocarcinoma of the stomach: are we making progress? Lancet. 1993 Sep 18;342(8873):713–718. doi: 10.1016/0140-6736(93)91711-t. [DOI] [PubMed] [Google Scholar]
  17. Weese J. L., Nussbaum M. L. Gastric cancer--surgical approach. Hematol Oncol. 1992 Jan-Feb;10(1):31–35. doi: 10.1002/hon.2900100107. [DOI] [PubMed] [Google Scholar]
  18. Wils J. A., Klein H. O., Wagener D. J., Bleiberg H., Reis H., Korsten F., Conroy T., Fickers M., Leyvraz S., Buyse M. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991 May;9(5):827–831. doi: 10.1200/JCO.1991.9.5.827. [DOI] [PubMed] [Google Scholar]
  19. Wils J., Bleiberg H., Dalesio O., Blijham G., Mulder N., Planting A., Splinter T., Duez N. An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol. 1986 Dec;4(12):1799–1803. doi: 10.1200/JCO.1986.4.12.1799. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES